Health care expenditure devoted to patients with HIV infection has changed considerably during the last decades because of the introduction of Highly Active Anti-Retroviral Therapy (HAART). It is estimated that the largest share of total costs in HIV treatment is attributable to HAART and significant differences in per patient cost are detectable across patients. The Ianua project is a regional study intended to investigate HAART cost effectiveness, evaluating both the per patient health care costs and their quality of life. The study concerns on the analysis of data referring to patients with HIV infection admitted to 3 infectious disease units in Genoa (Italy). With reference to each patient information regarding demographic characteristics, clinical pathways and quality of life is collected, the latter through an assessment of a (standardized) questionnaire
Cost assessment of haart: the ianua clinical trial in Genoa
AMERI, MARTA;Di Biagio, A.;GIACOMINI, MAURO;MONTEFIORI, MARCELLO;VISCOLI, CLAUDIO
2014-01-01
Abstract
Health care expenditure devoted to patients with HIV infection has changed considerably during the last decades because of the introduction of Highly Active Anti-Retroviral Therapy (HAART). It is estimated that the largest share of total costs in HIV treatment is attributable to HAART and significant differences in per patient cost are detectable across patients. The Ianua project is a regional study intended to investigate HAART cost effectiveness, evaluating both the per patient health care costs and their quality of life. The study concerns on the analysis of data referring to patients with HIV infection admitted to 3 infectious disease units in Genoa (Italy). With reference to each patient information regarding demographic characteristics, clinical pathways and quality of life is collected, the latter through an assessment of a (standardized) questionnaire
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
